Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 24

1.

Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET.

Rosa-Neto P, Doudet DJ, Cumming P.

Neuroimage. 2004 Jul;22(3):1076-83.

PMID:
15219579
2.

Learning networks in health and Parkinson's disease: reproducibility and treatment effects.

Carbon M, Ghilardi MF, Feigin A, Fukuda M, Silvestri G, Mentis MJ, Ghez C, Moeller JR, Eidelberg D.

Hum Brain Mapp. 2003 Jul;19(3):197-211.

PMID:
12811735
3.

Measurement of cortical dopamine d1 receptor binding with 11C[SCH23390]: a test-retest analysis.

Hirvonen J, Någren K, Kajander J, Hietala J.

J Cereb Blood Flow Metab. 2001 Oct;21(10):1146-50.

PMID:
11598491
4.
5.

Analysis of four dopaminergic tracers kinetics using two different tissue input function methods.

Sossi V, Holden JE, Chan G, Krzywinski M, Stoessl AJ, Ruth TJ.

J Cereb Blood Flow Metab. 2000 Apr;20(4):653-60.

PMID:
10779009
6.

Huntington's disease progression. PET and clinical observations.

Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brooks DJ.

Brain. 1999 Dec;122 ( Pt 12):2353-63.

PMID:
10581228
7.

Age-dependent decline of dopamine D1 receptors in human brain: a PET study.

Wang Y, Chan GL, Holden JE, Dobko T, Mak E, Schulzer M, Huser JM, Snow BJ, Ruth TJ, Calne DB, Stoessl AJ.

Synapse. 1998 Sep;30(1):56-61.

PMID:
9704881
8.

Reproducibility of the distribution of carbon-11-SCH 23390, a dopamine D1 receptor tracer, in normal subjects.

Chan GL, Holden JE, Stoessl AJ, Doudet DJ, Wang Y, Dobko T, Morrison KS, Huser JM, English C, Legg B, Schulzer M, Calne DB, Ruth TJ.

J Nucl Med. 1998 May;39(5):792-7.

9.

PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.

Ginovart N, Lundin A, Farde L, Halldin C, Bäckman L, Swahn CG, Pauli S, Sedvall G.

Brain. 1997 Mar;120 ( Pt 3):503-14.

PMID:
9126061
10.

Basal ganglia and movement disorders: an update.

Chesselet MF, Delfs JM.

Trends Neurosci. 1996 Oct;19(10):417-22. Review.

PMID:
8888518
11.

Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, Farde L.

Eur Arch Psychiatry Clin Neurosci. 1994;243(5):249-55.

PMID:
8172940
12.

Two dopamine receptors: biochemistry, physiology and pharmacology.

Stoof JC, Kebabian JW.

Life Sci. 1984 Dec 3;35(23):2281-96. Review.

PMID:
6390056
13.

Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.

Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A.

Life Sci. 1984 Oct 29;35(18):1885-93.

PMID:
6387355
14.

SCH 23390 - the first selective dopamine D-1 antagonist.

Hyttel J.

Eur J Pharmacol. 1983 Jul 15;91(1):153-4. No abstract available.

PMID:
6225651
15.

Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography.

Halldin C, Stone-Elander S, Farde L, Ehrin E, Fasth KJ, Långström B, Sedvall G.

Int J Rad Appl Instrum A. 1986;37(10):1039-43.

PMID:
3027000
16.
17.

PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.

Farde L, Halldin C, Stone-Elander S, Sedvall G.

Psychopharmacology (Berl). 1987;92(3):278-84.

PMID:
2957716
18.

Dopamine receptor subtype imbalance in schizophrenia.

Hess EJ, Bracha HS, Kleinman JE, Creese I.

Life Sci. 1987 Apr 13;40(15):1487-97.

PMID:
2951573
19.

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.

Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW.

Neuropsychopharmacology. 1987 Dec;1(1):5-15.

PMID:
2908095
20.

Selective dopamine D1 and D2 receptor antagonists.

Hyttel J, Arnt J, van den Berghe M.

Psychopharmacol Ser. 1989;7:109-22. Review. No abstract available.

PMID:
2574447

Supplemental Content

Support Center